BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37553346)

  • 1. Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice.
    Dasari V; McNeil LK; Beckett K; Solomon M; Ambalathingal G; Thuy TL; Panikkar A; Smith C; Steinbuck MP; Jakubowski A; Seenappa LM; Palmer E; Zhang J; Haqq CM; DeMuth PC; Khanna R
    Nat Commun; 2023 Aug; 14(1):4371. PubMed ID: 37553346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
    Cui X; Snapper CM
    Front Immunol; 2021; 12():734471. PubMed ID: 34691042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.
    Cui X; Cao Z; Sen G; Chattopadhyay G; Fuller DH; Fuller JT; Snapper DM; Snow AL; Mond JJ; Snapper CM
    Vaccine; 2013 Jun; 31(30):3039-45. PubMed ID: 23665339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computer-Aided Design of an Epitope-Based Vaccine against Epstein-Barr Virus.
    Alonso-Padilla J; Lafuente EM; Reche PA
    J Immunol Res; 2017; 2017():9363750. PubMed ID: 29119120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
    Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
    Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
    Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
    Front Immunol; 2018; 9():932. PubMed ID: 29765376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus.
    Wang M; Jiang S; Han Z; Zhao B; Wang L; Zhou Z; Wang Y
    Appl Microbiol Biotechnol; 2016 Feb; 100(3):1221-1230. PubMed ID: 26433969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge.
    Sashihara J; Hoshino Y; Bowman JJ; Krogmann T; Burbelo PD; Coffield VM; Kamrud K; Cohen JI
    PLoS Pathog; 2011 Oct; 7(10):e1002308. PubMed ID: 22028652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
    Perez EM; Foley J; Tison T; Silva R; Ogembo JG
    Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection.
    Catalina MD; Sullivan JL; Bak KR; Luzuriaga K
    J Immunol; 2001 Oct; 167(8):4450-7. PubMed ID: 11591771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.
    Heeke DS; Lin R; Rao E; Woo JC; McCarthy MP; Marshall JD
    Vaccine; 2016 May; 34(23):2562-9. PubMed ID: 27085175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
    Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
    J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a multiepitope plasmid DNA encoding T and B lymphocyte epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a vaccine in mice.
    Li W; Chen Q; Lin Q; Lv Y; Feng J; Liu J; Xu W; Chen S; Zhu X; Zhang L
    Protein Pept Lett; 2013 Oct; 20(10):1136-43. PubMed ID: 23688153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design.
    Khanna R; Sherritt M; Burrows SR
    J Immunol; 1999 Mar; 162(5):3063-9. PubMed ID: 10072559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with a Self-Assembled Nanoparticle Vaccine Elicits Potent Neutralizing Antibody Responses against EBV Infection.
    Kang YF; Zhang X; Yu XH; Zheng Q; Liu Z; Li JP; Sun C; Kong XW; Zhu QY; Chen HW; Huang Y; Xu M; Zhong Q; Zeng YX; Zeng MS
    Nano Lett; 2021 Mar; 21(6):2476-2486. PubMed ID: 33683126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
    Ning RJ; Xu XQ; Chan KH; Chiang AK
    Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoinformatics Approach to Design Novel Subunit Vaccine against the Epstein-Barr Virus.
    Moin AT; Patil RB; Tabassum T; Araf Y; Ullah MA; Snigdha HJ; Alam T; Alvey SA; Rudra B; Mina SA; Akter Y; Zhai J; Zheng C
    Microbiol Spectr; 2022 Oct; 10(5):e0115122. PubMed ID: 36094198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.